• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

指导临床药物开发的剂量和方案策略框架。

A framework to guide dose & regimen strategy for clinical drug development.

机构信息

Novartis Pharma AG, Basel, Switzerland.

Translational Medicine, Novartis Institutes for BioMedical Research, Basel, Switzerland.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2021 Nov;10(11):1276-1280. doi: 10.1002/psp4.12701. Epub 2021 Sep 25.

DOI:10.1002/psp4.12701
PMID:34562310
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8592517/
Abstract

Optimizing new drug therapies remains a challenge for clinical development, despite the use of ever more sophisticated quantitative methodologies. Although conceptually simple, the idea of finding the right treatment at the right dose for the right patient to ensure an appropriate balance of risks and benefits is challenging and requires a multidisciplinary approach. In this paper, we present a framework developed as a tool for organizing knowledge and facilitating collaboration in development teams.

摘要

尽管越来越多地使用复杂的定量方法,优化新药疗法仍然是临床开发面临的挑战。虽然概念上很简单,但要找到合适剂量的正确治疗方法,为合适的患者确保风险和收益的适当平衡,这是具有挑战性的,需要采用多学科方法。在本文中,我们提出了一个框架,作为开发团队组织知识和促进协作的工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9294/8592517/7480a2332863/PSP4-10-1276-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9294/8592517/08c6c18c5900/PSP4-10-1276-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9294/8592517/7480a2332863/PSP4-10-1276-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9294/8592517/08c6c18c5900/PSP4-10-1276-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9294/8592517/7480a2332863/PSP4-10-1276-g001.jpg

相似文献

1
A framework to guide dose & regimen strategy for clinical drug development.指导临床药物开发的剂量和方案策略框架。
CPT Pharmacometrics Syst Pharmacol. 2021 Nov;10(11):1276-1280. doi: 10.1002/psp4.12701. Epub 2021 Sep 25.
2
Right care, first time: a highly personalised and measurement-based care model to manage youth mental health.精准医疗,首次就诊:高度个性化和基于评估的青少年心理健康管理医疗模式。
Med J Aust. 2019 Nov;211 Suppl 9:S3-S46. doi: 10.5694/mja2.50383.
3
Tuberculosis结核病
4
Critical Care Network in the State of Qatar.卡塔尔国重症监护网络。
Qatar Med J. 2019 Nov 7;2019(2):2. doi: 10.5339/qmj.2019.qccc.2. eCollection 2019.
5
Contribution of the co.LAB Framework to the Collaborative Design of Serious Games: Mixed Methods Validation Study.co.LAB框架对严肃游戏协同设计的贡献:混合方法验证研究
JMIR Serious Games. 2021 Nov 24;9(4):e33144. doi: 10.2196/33144.
6
Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019.利用制剂和临床药理学知识提高儿科药物研发效率:M-CERSI 儿科制剂研讨会 2019 概述和讨论。
Eur J Pharm Biopharm. 2021 Jul;164:66-74. doi: 10.1016/j.ejpb.2021.04.010. Epub 2021 Apr 18.
7
Risk management frameworks for human health and environmental risks.人类健康与环境风险的风险管理框架。
J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. doi: 10.1080/10937400390208608.
8
Towards an appropriate framework to facilitate responsible inclusion of pregnant women in drug development programs.建立一个适当的框架,以促进孕妇合理参与药物研发项目。
Trials. 2018 Feb 20;19(1):123. doi: 10.1186/s13063-018-2495-9.
9
How partnership should work to bring innovative medicines to patients.如何建立合作伙伴关系,将创新药物带给患者。
Drug Discov Today. 2020 Jun;25(6):965-968. doi: 10.1016/j.drudis.2020.03.004. Epub 2020 Mar 12.
10
The optimization of combinatorial drug therapies: Strategies and laboratorial platforms.联合药物疗法的优化:策略与实验室平台
Drug Discov Today. 2021 Nov;26(11):2646-2659. doi: 10.1016/j.drudis.2021.07.023. Epub 2021 Jul 28.

引用本文的文献

1
Protocol Development for Investigator-Sponsored Clinical Studies.研究者发起的临床研究的方案制定
Clin Transl Sci. 2025 May;18(5):e70237. doi: 10.1111/cts.70237.
2
Harnessing Gasotransmitters to Combat Age-Related Oxidative Stress in Smooth Muscle and Endothelial Cells.利用气体信号分子对抗平滑肌和内皮细胞中与年龄相关的氧化应激
Pharmaceuticals (Basel). 2025 Feb 27;18(3):344. doi: 10.3390/ph18030344.
3
Dose Determinations at Drug Approval Reviews: FDA-Approved Drugs in Past 5 Years.药物审批审查中的剂量确定:过去5年获美国食品药品监督管理局批准的药物

本文引用的文献

1
Opportunities and pitfalls in clinical proof-of-concept: principles and examples.临床概念验证中的机遇与陷阱:原则与实例。
Drug Discov Today. 2018 Apr;23(4):776-787. doi: 10.1016/j.drudis.2018.01.045. Epub 2018 Feb 3.
2
Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014).药物研发期间剂量和给药方案确定的先进方法:欧洲药品管理局/欧洲制药工业协会联合会剂量确定研讨会总结(2014年12月4 - 5日,伦敦)
CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):418-429. doi: 10.1002/psp4.12196. Epub 2017 Jul 19.
3
Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
Clin Pharmacol Ther. 2025 Jun;117(6):1743-1753. doi: 10.1002/cpt.3611. Epub 2025 Feb 25.
4
Transplantation of Exosomes Derived From Human Wharton's Jelly Mesenchymal Stromal Cells Enhances Functional Improvement in Stroke Rats.人脐带华通氏胶间充质基质细胞来源外泌体移植可促进脑卒中大鼠功能改善。
Cell Transplant. 2024 Jan-Dec;33:9636897241296366. doi: 10.1177/09636897241296366.
5
A User-Driven Framework for Dose Selection in Pregnancy: Proof of Concept for Sertraline.一种用于孕期剂量选择的用户驱动框架:舍曲林的概念验证
Clin Pharmacol Ther. 2025 Jan;117(1):214-224. doi: 10.1002/cpt.3429. Epub 2024 Sep 9.
6
Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors.沙妥利单抗(MBG453)用于骨髓增生异常综合征/急性髓系白血病和实体瘤患者剂量选择的模型指导药物研发。
CPT Pharmacometrics Syst Pharmacol. 2023 Nov;12(11):1653-1665. doi: 10.1002/psp4.12962. Epub 2023 May 31.
7
Programmable self-regulated molecular buffers for precise sustained drug delivery.可编程自调节分子缓冲器,用于精确持续的药物输送。
Nat Commun. 2022 Nov 2;13(1):6504. doi: 10.1038/s41467-022-33491-7.
科学和监管原因导致新药首次申请延迟和被 FDA 否决,2000-2012 年。
JAMA. 2014;311(4):378-84. doi: 10.1001/jama.2013.282542.
4
Getting the Dose Right: report from the Tenth European Federation of Pharmaceutical Sciences (EUFEPS) conference on optimizing drug development.精准给药:第十届欧洲药物科学联合会(EUFEPS)优化药物研发会议报告
J Pharmacokinet Pharmacodyn. 2005 Apr;32(2):199-211. doi: 10.1007/s10928-005-0010-x. Epub 2005 Nov 7.
5
Combining multiple comparisons and modeling techniques in dose-response studies.在剂量反应研究中结合多种比较和建模技术。
Biometrics. 2005 Sep;61(3):738-48. doi: 10.1111/j.1541-0420.2005.00344.x.
6
Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.1980年至1999年期间499种经美国食品药品监督管理局批准的新分子实体的上市后药物剂量变化。
Pharmacoepidemiol Drug Saf. 2002 Sep;11(6):439-46. doi: 10.1002/pds.744.
7
Learning versus confirming in clinical drug development.临床药物研发中的学习与验证
Clin Pharmacol Ther. 1997 Mar;61(3):275-91. doi: 10.1016/S0009-9236(97)90160-0.